VYNE Therapeutics (NASDAQ:VYNE) Given Buy Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of VYNE Therapeutics (NASDAQ:VYNE) in a research report released on Wednesday,Benzinga reports. The brokerage currently has a $5.75 price objective on the stock.

Separately, BTIG Research initiated coverage on VYNE Therapeutics in a research report on Monday, November 18th. They set a “buy” rating and a $8.00 price objective on the stock.

VYNE Therapeutics Stock Up 0.8 %

VYNE stock opened at $2.52 on Wednesday. The business’s 50-day simple moving average is $2.81 and its 200 day simple moving average is $2.45. The company has a market cap of $37.17 million, a PE ratio of -2.93 and a beta of 1.28. VYNE Therapeutics has a twelve month low of $1.57 and a twelve month high of $4.30.

Insider Activity at VYNE Therapeutics

In other VYNE Therapeutics news, Director Patrick G. Lepore purchased 15,000 shares of the business’s stock in a transaction on Wednesday, January 15th. The stock was purchased at an average price of $2.92 per share, for a total transaction of $43,800.00. Following the completion of the purchase, the director now directly owns 51,472 shares in the company, valued at approximately $150,298.24. This trade represents a 41.13 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 4.80% of the stock is currently owned by insiders.

Hedge Funds Weigh In On VYNE Therapeutics

Hedge funds have recently modified their holdings of the stock. Acorn Capital Advisors LLC acquired a new stake in VYNE Therapeutics in the 4th quarter valued at $1,531,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in shares of VYNE Therapeutics during the fourth quarter valued at $823,000. Schonfeld Strategic Advisors LLC boosted its stake in shares of VYNE Therapeutics by 4.8% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 176,658 shares of the company’s stock valued at $592,000 after purchasing an additional 8,058 shares in the last quarter. Adage Capital Partners GP L.L.C. bought a new stake in shares of VYNE Therapeutics in the 4th quarter worth about $516,000. Finally, Bridgeway Capital Management LLC acquired a new stake in shares of VYNE Therapeutics during the 4th quarter worth about $124,000. 83.78% of the stock is owned by institutional investors and hedge funds.

VYNE Therapeutics Company Profile

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.